

Min Yan Teh, Elizabeth Ngoc Hoa Tran and Renato Morona

Absence of O antigen suppresses *Shigella flexneri* IcsA autochaperone region mutations

Microbiology, 2012; 158(11):2835-2850

© 2012 SGM

This is not the version of record of this article. This is an author accepted manuscript (AAM) that has been accepted for publication in *Microbiology* that has not been copy-edited, typeset or proofed. The Society for General Microbiology (SGM) does not permit the posting of AAMs for commercial use or systematic distribution. SGM disclaims any responsibility or liability for errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final version is available at <http://dx.doi.org/10.1099/mic.0.062471-0>, 2012.

PERMISSIONS

http://www.sgmjournals.org/site/misc/author_accepted_policy.xhtml

SGM Author Accepted Manuscript policy

The author accepted manuscript (AAM), also known as the ‘postprint’, includes modifications to the paper based on referees’ suggestions, before it has undergone copy editing, typesetting and proof correction.

Authors who do not choose immediate open access via the SGM Open option will sign a License to Publish agreement when their paper is accepted. The terms of the License enable authors to:

- retain the AAM for personal use;
- deposit the AAM in an institutional or subject repository (e.g. bioRxiv), provided that public availability is restricted until 12 months following publication of the final version.

SGM considers acceptable all forms of non-commercial re-use of AAMs in such repositories, including non-commercial text and data mining.

As a condition of acceptance in the journal, authors should take the following actions when depositing their AAM in a repository:

- include a [standard archiving statement](#) on the title page of the AAM;
- include a link to the final version of their article.

SGM does not permit:

- the posting of AAMs for commercial use or systematic distribution;
- the posting of the Version of Record (the final version published in the journal)

18 March 2015

1 **Title**

2 Absence of O-antigen suppresses *Shigella flexneri* IcsA autochaperone region mutations

3

4 **Running title**

5 IcsA autochaperone region mutations

6

7 **Authors**

8 Min Yan Teh, Elizabeth Ngoc Hoa Tran, and Renato Morona*

9

10 **Address**

11 Discipline of Microbiology and Immunology, School of Molecular and Biomedical Science,
12 University of Adelaide, Adelaide, South Australia, Australia 5005.

13

14 ***Corresponding Author**

15 Mailing address: Discipline of Microbiology and Immunology, School of Molecular and
16 Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia 5005.

17 Phone: + 61 (8) 8313 4151.

18 Fax: + 61 (8) 8313 7532.

19 E-mail: renato.morona@adelaide.edu.au.

20

21 Summary word count: 212

22 Main Text word count: 6940

23 Table and Figure count: 9

24 **Summary**

25 The *Shigella flexneri* *lcsA* (*VirG*) protein is a polarly distributed autotransporter protein.
26 *lcsA* functions as a virulence factor by interacting with the host actin regulatory protein, N-
27 WASP, which in turn activates the Arp2/3 complex, initiating actin polymerisation.
28 Formation of F-actin comet tails allows bacterial cell-to-cell spreading. Although various
29 accessory proteins such as periplasmic chaperones and the BAM complex have been
30 shown to be involved in the export of *lcsA*, the *lcsA* translocation mechanism remains to
31 be fully elucidated. A putative autochaperone (AC) region (aa 634-735) located at the C-
32 terminal end of the *lcsA* passenger domain, which forms part of the self-associating
33 autotransporter (SAAT) domain, has been suggested to be required for *lcsA* biogenesis,
34 as well as for N-WASP recruitment, based on mutagenesis studies. *lcsA_i* proteins with
35 linker insertion mutations within the AC region have a significant reduction in production
36 and are defective in N-WASP recruitment when expressed in smooth lipopolysaccharide
37 (S-LPS) *S. flexneri*. In this study, we have found that the LPS O-antigen (Oag) play a role
38 in *lcsA_i* production based on use of an *rmID* (*rfbD*) mutant having rough LPS (R-LPS), and
39 a novel assay in which Oag is depleted using tunicamycin treatment and then
40 regenerated. In addition, we have identified a new N-WASP binding/interaction site within
41 the *lcsA* AC region.

42

43 Introduction

44 *Shigella flexneri* is a Gram-negative bacterium that causes bacillary dysentery in humans
45 by infecting and colonising the colonic epithelium (Philpott *et al.*, 2000). IcsA (VirG) is an
46 essential virulence factor of *S. flexneri*. It is a polarly distributed 120 kDa outer membrane
47 (OM) protein that interacts with N-WASP, resulting in F-actin comet tail formation and
48 inter- and intracellular spreading of *S. flexneri* within the host intestinal epithelium
49 (Bernardini *et al.*, 1989; Lett *et al.*, 1989; Makino *et al.*, 1986; Sansonetti *et al.*, 1991;
50 Suzuki & Sasakawa, 2001).

51 IcsA is a member of the autotransporter (AT) family (Type Va secretion system), the
52 largest family of secreted proteins in Gram-negative bacteria (Henderson *et al.*, 2004;
53 Pallen *et al.*, 2003). Like other ATs, IcsA is composed of three major domains: an
54 extended N-terminal signal sequence (amino acids [aa] 1-52), a functional passenger α -
55 domain (aa 53-758), and a C-terminal translocation β -domain (aa 759-1102) that mediates
56 the translocation of the passenger domain across the OM via the BAM (beta-barrel
57 assembly machine) complex (Brandon *et al.*, 2003; Henderson *et al.*, 2004; Jain &
58 Goldberg, 2007; Peterson *et al.*, 2010; Suzuki *et al.*, 1995). The involvement of the BAM
59 complex and periplasmic chaperones such as DegP, Skp and SurA in IcsA translocation
60 suggest that the term 'autotransporter' is no longer applicable (Ieva & Bernstein, 2009;
61 Jain & Goldberg, 2007; Purdy *et al.*, 2007; Sauri *et al.*, 2009; Sklar *et al.*, 2007; Wagner *et*
62 *al.*, 2009). A common feature of AT proteins is that the exported passenger domain can be
63 cleaved and released into the external milieu or remain associated on the bacterial surface
64 (Henderson *et al.*, 2004). In *S. flexneri*, IcsP (SopA) is a virulence plasmid encoded serine
65 OM protease that cleaves surface IcsA at the Arg758-Arg759 bond position, releasing a
66 ~85 kDa IcsA fragment into the culture supernatant (d'Hauteville *et al.*, 1996; Fukuda *et*
67 *al.*, 1995; Steinhauer *et al.*, 1999). In spite of the diversity in sequence, function and

68 length, the passenger domains of most ATs possess a β -helical structure (Wells *et al.*,
69 2010).

70 *lcsA* has recently been classified as a member of the self-associating AT (SAAT) family,
71 together with other *Escherichia coli* ATs such as Ag43, AIDA-1, TibA and *Haemophilus*
72 *influenzae* Hap that mediate bacterial aggregation and biofilm formation (Klemm *et al.*,
73 2006; Meng *et al.*, 2011). In addition, a putative autochaperone (AC) region at the C-
74 terminal of the *lcsA* passenger domain (aa 634-735), which is part of the self-associating
75 domain, has been proposed to be required for *lcsA* biogenesis (May & Morona, 2008;
76 Meng *et al.*, 2011). The AC region is well conserved among many ATs and is essential for
77 AT secretion, folding and/or stability (May & Morona, 2008; Oliver *et al.*, 2003a; Oliver *et*
78 *al.*, 2003b; Yen *et al.*, 2008). While the crystal structure of the full length *lcsA* passenger
79 domain is not yet available, the *lcsA* AC region crystal structure (aa 591-758) has been
80 determined at 2.0-Å resolution and features two coils of a right-handed parallel β -helix
81 (Kuhnel & Diezmann, 2011). May & Morona (2008) have previously suggested that the
82 *lcsA* AC region is also an N-WASP interacting region (N-WASP IR III), based on linker-
83 insertion mutagenesis.

84 Lipopolysaccharide (LPS) is a major constituent of the Gram-negative bacteria OM and is
85 comprised of lipid A that is anchored into the OM, the core sugar region and the O-antigen
86 (Oag) polysaccharide repeat units that extends from the bacterial surface (Raetz &
87 Whitfield, 2002). The intact LPS molecules are known as smooth LPS (S-LPS), while LPS
88 molecules lacking the Oag, due to mutations affecting either the biosynthesis of Oag
89 repeat units (eg. *rmID/rfbD*) or their linkage to the core sugars, are known as rough LPS
90 (R-LPS) (Van Den Bosch *et al.*, 1997). LPS molecules are synthesised at the inner
91 membrane, and current models for the LPS biosynthesis pathway involve the MsbA ABC
92 transporter and the LPS transport (Lpt) pathway (Narita & Tokuda, 2009; Raetz &
93 Whitfield, 2002; Ruiz *et al.*, 2008; Ruiz *et al.*, 2009; Sperandio *et al.*, 2008; Tran *et al.*,

94 2010). *S. flexneri* LPS has been suggested to be required to reinforce lcsA polar
95 localisation and mask laterally located lcsA proteins (Morona & Van Den Bosch, 2003;
96 Robbins *et al.*, 2001; Sandlin *et al.*, 1995). However, the effect of LPS Oag in lcsA
97 translocation across the OM and its interaction with lcsA have not been reported.

98 The role of the lcsA putative AC/SAAT domain has not yet been fully investigated but we
99 have previously shown via linker-insertion mutagenesis that this region may play a role in
100 lcsA biogenesis (May & Morona, 2008). The production of AC lcsA_i (with insertion
101 mutations within the AC region) is significantly reduced in the S-LPS *S. flexneri* strain and
102 the strains were defective in recruiting N-WASP. In this study, we analysed the lcsA_i
103 production in both S-LPS and R-LPS *S. flexneri* to investigate the role of the AC
104 region/SAAT domain in lcsA biogenesis and N-WASP recruitment. We found that LPS
105 Oag affects the production of lcsA_i. Tunicamycin was used to suppress Oag synthesis,
106 and this restored lcsA_i production. Hence, Oag synthesis directly impacts lcsA_i biogenesis.
107 In addition, we investigated the mechanism underlying this and found that DegP protease
108 activity contributed to lack of lcsA_i production in the S-LPS background. Finally, we
109 identified a new N-WASP binding/interaction site within the previously identified N-WASP
110 IR III (aa 508-730).

111 **Methods**

112 *Bacterial strains and plasmids*

113 The strains and plasmids used in this study are listed in Table 1.

114

115 *Growth media and growth conditions*

116 All strains used in this study were routinely grown in Luria Bertani (LB). *S. flexneri* strains
117 were grown from a Congo Red positive colony except virulence plasmid-cured strains as
118 previously described (Morona *et al.*, 2003). Bacterial cultures were cultured for 18 h,
119 diluted 1:20 and grown to mid-exponential phase (2 h) with aeration at 37°C (unless
120 otherwise stated). Where appropriate, antibiotics were used at the following
121 concentrations: ampicillin (Ap, 100 µg mL⁻¹), chloramphenicol (Cm, 25 µg mL⁻¹),
122 kanamycin (Km, 50 µg mL⁻¹), streptomycin (Sm, 100 µg mL⁻¹) or tetracycline (Tet, 10 µg
123 mL⁻¹).

124

125 *DNA methods*

126 *E. coli* K-12 DH5α was used for all cloning. DNA manipulation, PCR, transformation and
127 electroporation into *S. flexneri* were performed as previously described (Baker *et al.*, 1999;
128 Morona *et al.*, 1995).

129

130 *Construction of pBAD33::icsP*

131 The *icsP* gene was amplified by PCR from *S. flexneri* 2457T chromosomal DNA (GenBank
132 #AF386526) using primers (ET22/ET25) with *KpnI* and *HindIII* restriction sites (Table S1).

133 The purified PCR product was subsequently cloned into the pBAD33 vector using the *KpnI*
134 and *HindIII* restriction sites.

135

136 *Antibodies and antisera*

137 Affinity purified rabbit polyclonal antibody to IcsA was produced as previously described
138 (Van Den Bosch *et al.*, 1997). The anti-IcsA antibody was used at 1:100 in
139 immunofluorescence (IF) assay or 1:1000 in Western immunoblotting (WB). The rabbit
140 polyclonal anti-Skp (1:6000), rabbit polyclonal anti-SurA (1:10,000) and rabbit polyclonal
141 anti-MBP-DegP antibodies are generous gifts from Thomas Silhavy (Princeton University),
142 Carol Gross (UCSF) and Michael Ehrmann (University of Duisburg-Essen), respectively.
143 Affinity purified rabbit polyclonal anti-IcsP antibody (1:1000) was produced by immunising
144 a rabbit with purified IcsP-His₆ protein. The protein was overexpressed in *E. coli* M15
145 containing pREP4 and IPTG-inducible pQE60-*icsP*. This plasmid was constructed by
146 cloning the *icsP* gene, which was PCR amplified from 2457T chromosomal DNA
147 (GenBank #AF386526) using primers (ET9/ET10) with *NcoI* and *BamHI* restriction sites
148 (Table S1), and cloned into the corresponding sites in pQE60 (Qiagen).

149

150 *IcsP protein induction*

151 18 h bacterial cultures were diluted 1:20 into 10 mL LB supplemented with 0.3% (w/v)
152 glucose and grown to mid-exponential phase with aeration at 37°C. Bacterial cultures were
153 centrifuged (2,200 xg, 10 min), the supernatant was discarded and cells were washed
154 twice with fresh LB prior to resuspension in 10 mL LB. Cultures were divided into 5 mL
155 aliquots, 0.3% (w/v) glucose (final concentration) was added into one aliquot as the no

156 IcsP expression control, while 0.2% (w/v) L-arabinose (final concentration) was added into
157 another aliquot to induce IcsP expression for 1 h at 37°C.

158

159 *Preparation of whole cell lysate*

160 The equivalent of 5×10^8 bacteria were centrifuged (2,200 $\times g$, 2 min), resuspended in 100
161 μL of 1x sample buffer (Lugtenberg *et al.*, 1975), and heated at 100°C for 5 min prior to
162 SDS-PAGE.

163

164 *TCA precipitation of culture supernatant*

165 TCA precipitation of culture supernatant was performed as described previously (May &
166 Morona, 2008). The equivalent of 5×10^8 bacteria were centrifuged, and the supernatant
167 was treated with 5% (w/v) ice-cold trichloroacetic acid (TCA), and incubated on ice. The
168 TCA precipitate was then collected by centrifugation (40,000 $\times g$, 30 min, 4°C), and the
169 pellet washed with ice-cold acetone prior to recentrifugation for 5 min. The pellet was air-
170 dried, resuspended in 100 μL of 1x sample buffer, and heated at 100°C for 5 min prior to
171 SDS-PAGE.

172

173 *Western transfer and detection*

174 Western immunoblotting was performed as described previously (May & Morona, 2008)
175 with some modifications. Briefly, proteins were separated on SDS-7.5%, 12% or 15%-
176 PAGE gels and transferred to a nitrocellulose membrane. The membrane was blocked
177 with 5% (w/v) skim milk in TTBS (Tris-buffered saline, 0.005% (v/v) Tween-20) for 20 min
178 and incubated with desired primary antibody in TTBS containing 2.5% (w/v) skim milk for

179 18 h. After three washes in TTBS, the membrane was incubated with horseradish
180 peroxidase-conjugated goat anti-rabbit secondary antibody (Biomediq DPC) for 2 h,
181 followed by three washes in TTBS, then three times in TBS. The membrane was incubated
182 with CPS3 chemiluminescence substrate (Sigma) for 5 min, followed by exposure of the
183 membrane to X-ray film (Agfa). The film was developed using a Curix 60 automatic X-ray
184 film processor (Agfa) or imaged with a Kodak Image Station 4000MM Pro (Carestream
185 Molecular Imaging) to visualise the reactive bands.

186

187 *Trypsin accessibility assay*

188 Limited proteolysis was performed as described previously (May & Morona, 2008; Oliver *et*
189 *al.*, 2003b) with modifications. The equivalent of 5×10^9 bacteria were centrifuged, the
190 supernatant discarded, and the pellet resuspended in 250 μ L PBS. Bacterial suspensions
191 were then treated with 0.1 μ g trypsin mL^{-1} (from bovine pancreas; Roche) and incubated at
192 25°C to allow proteolysis. Aliquots were taken at different time points (0 min, 5 min, 15 min
193 and 20 min) and supplemented with 1 mM phenylmethylsulphonyl fluoride (PMSF; Sigma)
194 to inhibit further proteolysis by trypsin. An equal volume of 2x sample buffer was added to
195 each sample, heated at 100 °C for 5 min prior to SDS-PAGE and Western immunoblotting
196 or storage at -20 °C.

197

198 *LPS and silver staining*

199 LPS samples were prepared as previously described (Murray *et al.*, 2003; Tsai & Frasch,
200 1982). Briefly, the equivalent of 1×10^9 bacteria were centrifuged (2,200 $\times g$, 2 min),
201 resuspended in 50 μ L lysing buffer (Papadopoulos & Morona, 2010) and incubated with
202 2.5 μ g proteinase K mL^{-1} (Invitrogen) for 16 h at 56°C. The LPS samples were

203 electrophoresed on a SDS-15%-PAGE gel for 16-18 h at 12 mA, and the gel was stained
204 with silver nitrate and developed with formaldehyde (Murray *et al.*, 2003).

205

206 *LPS depletion-regeneration assay*

207 18 h bacterial cultures were diluted 1:20 into LB and grown to mid-exponential phase with
208 aeration at 37°C. The bacterial strains were further diluted 1:20 into LB supplemented with
209 3 µg polymyxin B nonapeptide mL⁻¹ (PBMN; Sigma) and 10 µg tunicamycin mL⁻¹ (Sigma)
210 in DMSO, and treated for 3 h with aeration at 37°C (depletion phase). Bacterial cultures
211 were then centrifuged, washed twice with fresh LB to remove PMBN and tunicamycin
212 residues, and further diluted 1:20 into LB prior to additional incubation at 37°C with
213 aeration for another 3 h (regeneration phase). Samples were prepared for LPS analysis
214 and Western immunoblotting.

215

216 *Construction of a S. flexneri ΔicsA degP::Cm mutant strain*

217 The construction of *S. flexneri* ΔicsA degP::Cm mutant strain was performed as previously
218 described (Purins *et al.*, 2008). pRMA2802 [pCVD442-degP::Cm] was conjugated into
219 RMA2041, and sucrose/Cm/Tet-resistant and Ap-sensitive colonies were isolated and
220 named MYRM522. The degP::Cm mutation was confirmed by Western immunoblotting and
221 a temperature sensitivity phenotype.

222

223 *Site-directed mutagenesis*

224 Site-directed mutagenesis was performed according to the QuikChange[®] Lightning Site-
225 directed protocol (Stratagene). Specific primers with the desired substitutions were
226 designed (Table S1). Mutations were confirmed by DNA sequencing.

227

228 *Construction of the icsA-TGA-lacZ reporter*

229 The *Pst*I flanked *lacZ*-Km fragment from pKOK6.1 (Kokotek & Lotz, 1989; Murray *et al.*,
230 2003) was digested with *Pst*I and ligated into the compatible *Nsi*I site of *plcsA* (Van Den
231 Bosch & Morona, 2003) (nt 221623 and nt 225138, GenBank #AF386526) to give the
232 *PicsA-lacZ* construct, pMYRM632. The transcriptional *PicsA-TGA-lacZ* reporter plasmid
233 was created by mutating an amino acid between the *icsA* sequence and *lacZ* sequence of
234 *PicsA-lacZ* into a stop codon (TGA) via site-directed mutagenesis, as described above,
235 with primer pairs listed in Table S1. The resultant construct was named pMYRM676. The
236 *Pst*I-*Sal*I fragment from pMYRM676 which contains the *PicsA-TGA-lacZ* fragment, was
237 subsequently cloned into the likewise digested pSU23 vector to obtain the transcriptional
238 reporter plasmid, pMYRM718.

239

240 *β-galactosidase assay*

241 The β-galactosidase assay was performed using the Miller protocol (Miller, 1972) with
242 some modifications. 18 h bacterial cultures were diluted 1:20 into 10 mL LB and grown to
243 mid-exponential phase with aeration at 37°C. The OD₆₀₀ of bacterial culture was
244 measured, 1 mL sample was taken, centrifuged, the supernatant discarded and the pellet
245 resuspended in Z buffer. Cells were permeabilised by adding 20 μL 0.1% (w/v) SDS and
246 40 μL chloroform and mixed vigorously for 10 sec. 120 μL samples were dispensed into a
247 96 well microtitre tray in triplicates and 24 μL 7 mg ortho-Nitrophenyl-β-galactoside mL⁻¹

248 (ONPG) was added into each well. Samples were incubated at 37°C for 3 h and readings
249 (OD₄₂₀ and OD₅₅₀) were taken at 2 min intervals. Units of activity were calculated as
250 previously described (Miller, 1972).

251

252 *Indirect immunofluorescence of whole bacteria*

253 Indirect IF labelling of bacteria was performed as described previously (May & Morona,
254 2008). Briefly, mid-exponential phase bacteria were fixed in 3.7% (v/v) formalin and
255 centrifuged onto poly-L-lysine-coated coverslips. Bacteria were incubated with anti-IcsA
256 antibody diluted 1:100 in PBS with 10% (v/v) foetal calf serum (FCS), washed with PBS
257 and labelled with Alexa 488-conjugated donkey anti-rabbit secondary antibody (Molecular
258 Probes) (1:100). Microscopy was performed using an Olympus IX-70 microscope with
259 phase-contrast optics using a 100x oil immersion objective. Fluorescence and phase-
260 contrast images were false colour merged using the Metamorph software program
261 (Version 7.7.3.0, Molecular Devices).

262

263 *Infection of tissue culture monolayers with S. flexneri and IF labelling*

264 Infection of HeLa cell monolayers and IF staining were performed as described previously
265 (May & Morona, 2008). Briefly, HeLa monolayers were inoculated with mid-exponential
266 phase bacteria and incubated for 1 h at 37°C, 5% CO₂. The infected monolayers were
267 washed three times with D-PBS and incubated with MEM containing gentamycin for a
268 further 1.5 h. Infected cells were then washed and fixed for 15 min in 3.7% (v/v) formalin,
269 incubated with 50 mM NH₄Cl in D-PBS for 10 min, and permeabilised with 0.1% (v/v)
270 Triton X-100 for 5 min. The infected cells were blocked with 10% (v/v) FCS in PBS and
271 incubated with anti-N-WASP antibody. After washing in PBS, coverslips were incubated

272 with Alexa Fluor 594-conjugated donkey anti-rabbit secondary antibody (Molecular
273 Probes) (1:100). F-actin was visualised by staining with Alexa Fluor 488-conjugated
274 phalloidin (2 U mL^{-1}), and 4',6'-diamidino-2-phenylindole (DAPI) ($10 \text{ } \mu\text{g mL}^{-1}$) was used to
275 counterstain bacteria and cellular nuclei.

276 **Results**

277 *IcsA_i mutant production is restored in S. flexneri ΔicsA ΔrmID*

278 LPS is known to mask surface IcsA function (Morona *et al.*, 2003; Morona & Van Den
279 Bosch, 2003). May & Morona (2008) also reported that S-LPS can affect N-WASP
280 recruitment and F-actin comet tail formation, by expressing certain IcsA_i (outside the AC
281 region) and IcsA deletion mutants in a R-LPS *S. flexneri* strain. Hence, four previously
282 identified IcsA_i mutants with 5 aa insertion within the AC region (IcsA_{i633}, IcsA_{i643}, IcsA_{i677},
283 and IcsA₇₁₆) which had defects in protein production and N-WASP recruitment when
284 expressed in *S. flexneri* ΔicsA S-LPS (RMA2041) (May & Morona, 2008), were re-
285 examined in this study. The mutants were expressed in *S. flexneri* ΔicsA ΔrmID R-LPS
286 strain (RMA2043) and the IcsA_i protein production was assessed by Western
287 immunoblotting.

288 As previously reported, IcsA_{i633}, IcsA_{i643} and IcsA_{i677} were poorly detected while IcsA_{i716}
289 could not be detected when expressed in *S. flexneri* ΔicsA S-LPS strain (Fig. 1a, lanes 3,
290 5, 7 and 9). Surprisingly, IcsA_i mutant production in *S. flexneri* ΔicsA ΔrmID R-LPS strain
291 was restored to a near wild-type (WT) levels (Fig. 1a, lanes 4, 6, 8, and 10), which were
292 consistent with the results obtained by IF microscopy (Fig. 1b). IcsA_{i716} protein expression
293 on the surface of *S. flexneri* ΔicsA strain was poorly detectable (Fig. 1b(iii)), in comparison
294 to the high level of IcsA_{i716} detected on *S. flexneri* ΔicsA ΔrmID strain (Fig. 1b(iv)); it was
295 also noted that IcsA_{i716} has a polar localisation, like IcsA_{WT} (Fig. 1b(i,ii)). Similar results
296 were obtained for IcsA_{i633}, IcsA_{i643}, and IcsA_{i677} (data not shown). IcsA staining was not
297 observed for RMA2041 (ΔicsA) and RMA2043 (ΔicsA ΔrmID), indicating the anti-IcsA
298 antibody is specifically targeting the IcsA protein (Fig. 1b(v,vi)).

299

300 *rmID complementation*

301 The *rmID* (also known as *rfbD*) gene encodes for dTDP-6-deoxy-L-mannose
302 dehydrogenase which is involved in the synthesis of the nucleotide sugar dTDP-rhamnose
303 that is the precursor for rhamnose in the *S. flexneri* Oag repeat units (Reeves *et al.*, 1996).
304 To determine if the effect of *rmID* on the *IcsA_i* expression is directly related to the
305 Δ *rmID*::Km mutation, *S. flexneri* Δ *icsA* Δ *rmID* R-LPS strains expressing either *IcsA_{WT}*, or
306 various *IcsA_i* were complemented with *rmID* carried by pRMA727. As a control, the same
307 *S. flexneri* strains were transformed with the empty vector, pACYC184. The LPS profile
308 and *IcsA* production of the resultant strains was subsequently determined. *S. flexneri*
309 Δ *rmID* strains were successfully complemented by pRMA727 which restored their S-LPS
310 profile (Fig. 2a, lanes 2, 4, 6, 8 and 10), while strains that were transformed with
311 pACYC184 retained their R-LPS profile (Fig. 2a, lanes 1, 3, 5, 7 and 9). As seen in Fig. 2b,
312 *rmID* complementation also reverted *IcsA_i* production to very low level as seen in the S-
313 LPS background, compared to the R-LPS strains. *IcsA_{WT}* production remained unaffected
314 in both S-LPS and R-LPS backgrounds. In another experiment, very low levels of *IcsA_i*
315 production was also observed in the *E. coli* K-12 *ompT*⁻ UT5600 strains that were
316 complemented to produce S-LPS but had higher *IcsA_i* protein expression in the R-LPS
317 background (Fig. S1). Hence, the presence and absence of Oag chains results in an
318 inverse *IcsA_i* production in both *S. flexneri* and *E. coli* K-12 *ompT*⁻ strain backgrounds.

319

320 *Effect of LPS Oag modulation on IcsA_{i716} mutant production*

321 The *rmID* complementation assay showed that LPS Oag synthesis affects *IcsA_i* mutant
322 production in *S. flexneri*. To independently verify the effect of LPS Oag on *IcsA_i* mutant
323 production, a novel LPS Oag depletion-regeneration assay was developed, as described
324 in the Methods, and performed on a *S. flexneri* Δ *icsA* strain expressing either *IcsA_{WT}* or
325 *IcsA_{i716}*. Tunicamycin was used at a concentration of 10 μ g mL⁻¹ (in DMSO) in conjunction

326 with 3 μg polymyxin B nonapeptide mL^{-1} (PMBN) to inhibit Oag biosynthesis. The
327 subsequent removal of tunicamycin and PMBN resulted in regeneration of Oags.
328 Tunicamycin is a nucleoside antibiotic that inhibits the WecA enzyme (N-
329 acetylglucosamine-1-phosphate transferase) which is involved in the first step of Oag
330 biosynthesis (Alexander & Valvano, 1994; Brandish *et al.*, 1996). PMBN is a non-toxic
331 peptide derivative of polymyxin B which helps to permeabilise the OM of Gram-negative
332 bacteria and facilitates the entry of hydrophobic tunicamycin into the bacterial cell (Vaara
333 & Vaara, 1983; Vaara, 1992). LPS silver staining showed that Oag biosynthesis was
334 significantly inhibited by approximately 90% after 3 h of treatment with tunicamycin/PMBN
335 (Fig. 3a, lanes 2 and 7), while the Oag production was restored upon the removal of
336 tunicamycin/PMBN (Fig. 3a, lanes 3 and 8). Oag biosynthesis in strains treated with
337 DMSO only (negative control) remained unchanged (Fig. 3a, lanes 4-5 and 9-10,
338 respectively).

339 Western immunoblotting showed that IcsA_{WT} protein was produced regardless of the
340 tunicamycin/PMBN treatment (Fig. 3b, lanes 1-5). In contrast, while $\text{IcsA}_{\text{i716}}$ mutant
341 production was hardly detectable when the strain was untreated (Fig. 3b, lane 6) or treated
342 with DMSO (Fig. 3b, lanes 9-10), a full length 120 kDa $\text{IcsA}_{\text{i716}}$ band was readily detected
343 when the LPS Oag biosynthesis was inhibited (Fig. 3b, lane 7). As expected, the $\text{IcsA}_{\text{i716}}$
344 band was no longer detectable when the LPS Oags were regenerated (Fig. 3b, lane 8).
345 Overall, these results indicate that LPS Oags affect IcsA_i mutant production in the S-LPS
346 *S. flexneri*. The potential mechanism(s) involved were investigated as described below.

347
348 Effect of IcsP on IcsA_i expression in S-LPS and R-LPS *S. flexneri*

349 The locations of the 5 aa linker-insertion mutations in the IcsA AC region are in close
350 proximity to the IcsP cleavage site (aa 758-759). Therefore, we hypothesised that the IcsP

351 cleavage site of IcsA_i may be altered and/or became more accessible to IcsP which may
352 cleave IcsA_i more readily in the S-LPS background. To test our hypothesis, IcsA_{i716} was
353 selected and the amount of IcsA' protein (cleaved form) in the culture supernatants of both
354 S-LPS and R-LPS backgrounds was investigated. The cleaved form of IcsA_{i716} was not
355 detected in the S-LPS background (Fig. 4a, lane 6) but was observed in the R-LPS
356 background (Fig. 4a, lane 8), at a similar level to that seen for IcsA_{WT} protein in both
357 backgrounds (Fig. 4a, lanes 2 and 4).

358 We also investigated the effect of the presence and absence of IcsP in virulence plasmid-
359 cured (VP^{-ve}) S-LPS and R-LPS backgrounds. Results consistent with the above were
360 obtained when various IcsA_i proteins were expressed in VP^{-ve} S-LPS and VP^{-ve} R-LPS *S.*
361 *flexneri* strain carrying pBAD33::*icsP*. IcsA_i production in *S. flexneri* VP⁻ S-LPS remained
362 extremely low and was not restored to IcsA_{WT} levels despite the absence of IcsP (Fig. 4b).
363 In contrast, *S. flexneri* VP⁻ R-LPS background showed production of IcsA_i proteins at WT
364 level (except IcsA_{i634} which showed slightly lower levels of protein production than IcsA_{WT})
365 when IcsP was absent (Fig. 4c). Interestingly, the IcsA_i proteins appeared to be more
366 sensitive to IcsP cleavage than IcsA_{WT} as a reduction in the full length IcsA_i mutant
367 proteins (120 kDa) was observed when IcsP was induced (Fig. 4c, lanes 4, 6, 8, and 10).
368 The IcsA_{i643} mutant in particular, appeared to be more sensitive to IcsP cleavage
369 compared to the other IcsA_i proteins (Fig. 4c, lane 6). The levels of the cleaved form of
370 IcsA_i' (85 kDa) that remained associated with bacterial cells were comparable to IcsA'_{WT}
371 (Fig. 4c). These data suggest that IcsP does not have a major role in reducing IcsA_i
372 production in the S-LPS background and most IcsA_i proteins are more sensitive to IcsP
373 cleavage than IcsA_{WT}, possibly due to a change in protein conformation.

374

375 *icsA promoter activity*

376 To determine if the *icsA* promoter activity is upregulated in the R-LPS background and
377 contributing to the high *IcsA_i* mutant expression level, we created a transcriptional reporter
378 plasmid pMYRM718 [*PicsA-TGA-lacZ*], encoding an *icsA* promoter fusion with *lacZ* in
379 pSU23, as described in the Methods. Both S-LPS and R-LPS *S. flexneri* strains carrying
380 either *plcsA_{WT}* or *plcsA_{i716}* were transformed with pMYRM718, to give strains MYRM734
381 (S-LPS + *plcsA_{WT}* + *PicsA-TGA-lacZ*), MYRM721 (R-LPS + *plcsA_{WT}* + *PicsA-TGA-lacZ*),
382 MYRM722 (S-LPS + *plcsA_{i716}* + *PicsA-TGA-lacZ*) and MYRM723 (R-LPS + *plcsA_{i716}* +
383 *PicsA-TGA-lacZ*), respectively. Each strain was grown to mid-exponential phase and β -
384 galactosidase levels were assayed. LacZ activity was measured in the presence of either
385 *IcsA_{WT}* or *IcsA_{i716}* because the presence of a misfolded protein might create a feedback
386 loop to activate *icsA* promoter activity or gene expression. The data show that there was
387 no significant difference in *icsA* promoter activity between MYRM734 and MYRM721 (in
388 the presence of *IcsA_{WT}*), while the *icsA* promoter activity was slightly higher in MYRM722
389 than MYRM723 (in the presence of *IcsA_{i716}*) ($*P < 0.5$) (Fig. 5). The data suggest that the
390 very low *IcsA_i* protein production in the S-LPS background is unlikely due to an effect of
391 transcriptional level, but may be due to a post-transcriptional effect, such as increased
392 proteolysis.

393

394 *IcsA_{i716}* mutant production in a *S. flexneri* *degP::Cm ΔicsA* S-LPS strain

395 Since the OM protease, *IcsP*, did not appear to cause the low *IcsA_i* mutant production in
396 S-LPS *S. flexneri*, we hypothesised that the translocation of *IcsA_i*-periplasmic intermediate
397 across the OM is retarded in such a way that prolonged exposure to periplasmic
398 proteases, such as *DegP*, degrades the *IcsA_i*-periplasmic intermediate. *DegP* is a
399 temperature regulated bifunctional periplasmic protein that may act as a chaperone or a
400 protease at 37 °C but as a chaperone at low temperature (Spiess *et al.*, 1999). A S-LPS *S.*

401 *flexneri degP::Cm ΔicsA* mutant strain was created as described in the Methods and the
402 strain was subsequently complemented with *plcsA_{WT}* or *plcsA_{i716}*. The resultant strains
403 expressing either *IcsA_{WT}* or *IcsA_{i716}* were grown to mid-exponential phase at 30°C or 37°C
404 and the production of *IcsA* was assessed by Western immunoblotting. Protein production
405 of *IcsA_{i716}* was partly restored in the *ΔdegP* background at both 30°C and 37°C (Fig. 6,
406 lanes 5 and 6), in comparison to *IcsA_{WT}* (Fig. 6, lanes 3 and 4). The data suggest that in
407 the presence of LPS Oag, *DegP* protease is largely responsible for degrading the *IcsA_i*
408 mutant protein.

409

410 *Expression of DegP, Skp and SurA periplasmic chaperones in S-LPS and R-LPS S.*
411 *flexneri*

412 The expression of periplasmic chaperones such as *DegP*, *Skp* and *SurA* are regulated by
413 the σ^E envelope stress response or the *Cpx* two-component signal transduction system
414 (Duguay & Silhavy, 2004; Raivio & Silhavy, 2001; Rhodius *et al.*, 2006). In comparison to
415 a *S. flexneri ΔicsA* S-LPS strain, the *S. flexneri ΔicsA ΔrmID* R-LPS strain (which has the
416 *rmID* gene deleted) might be under stress and hence, may have upregulated periplasmic
417 chaperone expression. Therefore, the expression level of *DegP*, *Skp* and *SurA* in both S-
418 LPS and R-LPS *S. flexneri* (in the presence or absence of *IcsA_{WT}* or *IcsA_{i716}*), were
419 examined. The production of *DegP*, *Skp* and *SurA* was not upregulated in the R-LPS
420 background (Fig. S2) even in the presence of *IcsA_{i716}* protein, indicating a lack of cell
421 envelope stress response. However, this does not exclude that their chaperone activity is
422 not being upregulated in the R-LPS strain. Likewise, *DegP* proteolysis activity in the S-LPS
423 background may be upregulated in the presence of *IcsA_i* mutant protein.

424

425 *Effect of AC region insertion mutations on IcsA_i functionality in S. flexneri ΔicsA ΔrmID*

426 The N-WASP recruitment ability of various *IcsA_i* AC mutants expressed by R-LPS *S.*
427 *flexneri* was investigated to determine if the proteins retained their function. R-LPS *S.*
428 *flexneri* expressing *IcsA_{WT}* or various *IcsA_i* were used to infect HeLa cells and N-WASP
429 recruitment was detected as described in the Methods. Except the *IcsA_{i716}* mutant (Fig. 7f),
430 *IcsA_{i633}*, *IcsA_{i643}* and *IcsA_{i677}* (Fig. 7d) (Data for *IcsA_{i633}*, *IcsA_{i643}* not shown) mutants
431 recruited N-WASP and formed F-actin comet tails within HeLa cells, suggesting that
432 *IcsA_{i633}*, *IcsA_{i643}* and *IcsA_{i677}* have WT protein conformation and are functional. In contrast,
433 despite the high level of *IcsA_{i716}* protein detected on the bacterial surface of LB grown cells
434 (Fig. 1b), neither N-WASP nor F-actin comet tails were detected (Fig. 7f), suggesting that
435 an N-WASP binding/interacting site could be located at aa 716-717. Alternatively, *IcsA_{i716}*
436 might be highly misfolded, thus, masking the N-WASP binding/interacting sites and
437 inhibiting F-actin comet tail formation. Data for S-LPS *S. flexneri* expressing *IcsA_{WT}*,
438 *IcsA_{i677}*, and *IcsA_{i716}* are shown for comparison (Fig. 7a, c and e).

439

440 *Potential effect of insertion mutations on IcsA_i protein folding*

441 As the 5 aa linker-insertion mutations might result in altered *IcsA_i* protein conformations
442 and affect N-WASP recruitment ability, the protein conformation of *IcsA_i* was investigated.
443 *S. flexneri* Δ *icsA* Δ *rmID* expressing either *IcsA_{WT}* or *IcsA_i* were subjected to 1 μ g trypsin
444 mL⁻¹ over a period of time (0 min, 5 min, 15 min and 20 min). A misfolded protein could be
445 more sensitive to trypsin degradation, giving a different proteolysis profile than *IcsA_{WT}* in
446 Western immunoblotting. The results of limited proteolysis assay (Fig. 8) suggest that all
447 tested *IcsA_i* mutants do not have major difference to the *IcsA_{WT}* profile. In spite of the
448 similar proteolysis profiles, *IcsA_{i643}* and *IcsA_{i716}* seem to be more sensitive to trypsin
449 degradation, as the overall *IcsA* band profile intensity for these *IcsA_i* mutants was
450 significantly reduced after 15 min of trypsin digestion (Fig. 8, lanes 11 and 19), whilst
451 *IcsA_{i633}* and *IcsA_{i677}* had a WT proteolysis profile (Fig. 8, lanes 5-8 and 13-16,

452 respectively). The data suggest that the *IcsA_i* mutants do not have major change in
453 conformation. Furthermore, our laboratory has recently shown that the *S. flexneri* *IcsA*
454 protein is able to self-associate and form a complex in the OM (May *et al.*, 2012). Thus,
455 DSP chemical cross-linking was performed to examine if the *IcsA_i* mutants retain their self-
456 association ability. The results showed that all tested *IcsA_i* mutants formed high molecular
457 weight proteins like *IcsA_{WT}* (data not shown), indicating that the mutants possess WT
458 protein conformation, which is consistent with the results obtained from the trypsin
459 accessibility assay, and the ability to recruit N-WASP (except for *IcsA_{i716}*).

460

461 Discussion

462 The IcsA (VirG) protein of *S. flexneri* is a Type Va autotransporter protein (Henderson *et al.*, 2004) that allows *S. flexneri* to spread between the host intestinal epithelial cells
463 (Bernardini *et al.*, 1989; Goldberg *et al.*, 1993; Goldberg, 2001; Lett *et al.*, 1989). IcsA
464 hijacks the host actin regulatory protein, N-WASP, and forms F-actin comet tails at one
465 pole of the bacterium that propel *Shigella* in the opposite direction (Bernardini *et al.*, 1989;
466 Brandon *et al.*, 2003).

468 The translocation mechanism of various OMPs or ATs has been studied extensively in *E.*
469 *coli* (Ieva *et al.*, 2011; Peterson *et al.*, 2010; Ruiz-Perez *et al.*, 2010; Soprova *et al.*, 2010;
470 Walton *et al.*, 2009). However, the detailed mechanisms of IcsA biogenesis have not been
471 fully elucidated. In this study, N-WASP recruitment ability and the role of the AC region in
472 IcsA biogenesis was investigated in both S-LPS and R-LPS backgrounds, and differs
473 markedly from other studies on AC regions in this regard.

474 The restoration of AC IcsA_i mutant production in R-LPS *S. flexneri* allowed us to examine
475 N-WASP recruitment ability, and IcsA_{i716} which possesses 5 aa insertion at the Aro₇₁₆-X₇₁₇-
476 Aro₇₁₈ motif was identified as defective in N-WASP recruitment. This suggests that either
477 residues 716-717 is an N-WASP binding/interaction site, or IcsA_{i716} is severely misfolded
478 and masked the N-WASP binding sites. Both IcsA_{i643} and IcsA_{i716} demonstrated a slightly
479 increased sensitivity to trypsin degradation but had a proteolysis profile similar to the WT
480 (Fig. 8). This could be due to the presence of arginine residue in the inserted 5 aa
481 sequence (Table S2), which is a trypsin cleavage site. However, IcsA_{i643} is able to recruit
482 N-WASP despite the increased sensitivity to trypsin. This result implies that any alteration
483 in protein conformation is limited. Thus, IcsA_{i716} which has a similar proteolysis profile to
484 IcsA_{i643} is likely to also possess a near WT conformation. Moreover, high molecular IcsA_i
485 complexes were detected in DSP chemical cross-linking (data not shown), and suggests

486 that all *IcsA_i* AC mutants are able to self-associate and have a conformation similar to WT.
487 Taken together, all *IcsA_i* AC mutants do not have major alteration in protein conformation.
488 The data also suggest that an N-WASP binding/interacting site is located at residues 716-
489 717. This has been confirmed by site-directed mutagenesis of aa 716-717, and functional
490 complementation of an N-WASP interacting region II mutant *IcsA* protein (Teh and
491 Morona, unpublished data).

492 Mutations within the *IcsA* AC region significantly affected *IcsA_i* production in the *S. flexneri*
493 S-LPS background (May & Morona, 2008) but not in the R-LPS background (Fig. 1). This
494 finding was supported by *rmID* complementation assay which generated the same
495 phenotype (Fig. 2), as well as expression of various *IcsA_i* mutants in the *E. coli* K-12
496 *ompT* UT5600 strain (with or without S-LPS) (Fig. S1). These data demonstrate that the
497 presence of LPS Oag affects biogenesis of *IcsA_i* proteins with mutations within the AC
498 region, independent of *S. flexneri*-specific virulence determinants, as the *IcsA_i* phenotype
499 was reproduced in VP^{-ve} *S. flexneri* and in UT5600 strain backgrounds. In addition, we
500 showed that the very low level of *IcsA_i* production in the S-LPS background was not due to
501 extensive *IcsP* cleavage. Therefore, to directly investigate the effect of LPS Oag on *IcsA_i*
502 mutant production, an LPS depletion-regeneration assay was undertaken. We
503 demonstrated that the depletion of Oag restored *IcsA_i* mutant production and the effect
504 was reversible (Fig. 3). The data suggests that the presence of Oag affects *IcsA*
505 biogenesis in an unknown mechanism and possibly plays an unidentified new role in the
506 *IcsA* translocation system. LPS Oag has never been shown to interact with either the
507 exported *IcsA* or *IcsA*-periplasmic intermediate.

508 Our findings show that the *icsA* promoter activity was not downregulated in S-LPS *S.*
509 *flexneri* in the presence of *IcsA_{WT}* or *IcsA_i* AC mutant, indicating the differences in *IcsA_i*
510 production between the S-LPS and R-LPS backgrounds was not due to a general effect on

511 the transcription of AC *IcsA_i*. These data suggest that a post-transcriptional effect is
512 involved in affecting AC *IcsA_i* production in the S-LPS strain background.

513 The presence of a transient soluble *IcsA*-periplasmic intermediate has previously been
514 reported (Brandon & Goldberg, 2001) and periplasmic chaperones such as DegP, Skp and
515 SurA are required for proper *IcsA* presentation (Purdy *et al.*, 2002; Purdy *et al.*, 2007).
516 DegP which is also a protease was reported to degrade unproductive or misfolded OMPs
517 in the periplasm (Kolmar *et al.*, 1996; Soprova *et al.*, 2010). As shown in Fig. 6, *IcsA_i*
518 protein production was restored by a $\Delta degP$ mutant in the S-LPS background, suggesting
519 that *IcsA_i*-periplasmic intermediate was sensitive to DegP degradation in the presence of
520 LPS Oag. In addition, we showed that the DegP expression level (as well as Skp and
521 SurA) remained the same between S-LPS and R-LPS backgrounds even in the presence
522 of *IcsA_i* AC protein. It is possible that DegP could be less active as a protease in the R-
523 LPS background or vice versa in the S-LPS background. However, there are no reports of
524 DegP having LPS-dependent activity. Hence, it is unclear how S-LPS may be affecting
525 DegP and hence, *IcsA_i* AC mutant protein production.

526 We speculate that an early interaction occurs between the Skp-*IcsA_i* complex with
527 transiting S-LPS or R-LPS molecules in the periplasm, via the putative LPS binding site on
528 the outer surface of Skp (Korndorfer *et al.*, 2004; Walton & Sousa, 2004). This interaction
529 may promote dissociation of *IcsA_i* from Skp due to a weak interaction caused by the *IcsA_i*
530 AC mutations. The released and unprotected *IcsA_i* mutant might then be rapidly
531 aggregated and become degraded by DegP. On the other hand, binding of R-LPS
532 molecule to the Skp-*IcsA_i* complex would not promote *IcsA_i* dissociation; this could be a
533 function of Oag polysaccharide chains. Interestingly, Oag polysaccharides are a substrate
534 for bacteriophage tailspike protein (TSP) that have a right-handed parallel β -helix structure
535 (Steinbacher *et al.*, 1996) which is similar to the predicted *IcsA* structure (Kuhnel &
536 Diezmann, 2011), and that of other ATs (Emsley *et al.*, 1996; Johnson *et al.*, 2009; Khan

537 *et al.*, 2011; Otto *et al.*, 2005). Another possibility is that a third unknown factor which is
538 affected by Oag is involved in influencing IcsA_i interaction with chaperones. Nonetheless,
539 this hypothetical model warrants further investigation, as interaction between Skp and LPS
540 has not been shown *in vivo*, and no data suggesting Skp binding to AC region of IcsA
541 have been reported.

542 Even though IcsA_{i716} production was restored in the *S. flexneri* $\Delta degP$ strain, the degree of
543 IcsA_{i716} restoration was not 100% (Fig. 6), and this could be due to the location of the
544 insertion mutation. Residue Y716 is part of the Aro-X-Aro motif which is a preferential SurA
545 binding site (Bitto & McKay, 2003; Xu *et al.*, 2007) and based on the IcsA AC crystal
546 structure, residue Y716 is predicted to be located at the beginning of the first anti-parallel
547 β -strand which appears to be exposed to the external medium (Fig. S3). Direct interaction
548 between IcsA and SurA has not been reported, and if residues 716-718 were a SurA
549 binding site, we speculate that the 5 aa insertion mutation might have altered this potential
550 SurA binding site and reduced the chaperone protection from SurA during the
551 translocation of IcsA passenger domain across the OM, hence, reducing IcsA_{i716}
552 production. Again, the assumption of interaction between SurA and IcsA AC region
553 requires further investigations. Alternatively, IcsA_{i716} could be degraded by other
554 periplasmic protease such as DegQ. In comparison, triple Aro-X-Aro motif mutations in the
555 *E. coli* AT EspP passenger domain were required to observe a reduction in the EspP
556 secretion (Ruiz-Perez *et al.*, 2009), suggesting that the effect of Aro-X-Aro motif in IcsA is
557 more significant than in EspP.

558 We have demonstrated for the first time that the presence of LPS Oag affects protein
559 production of IcsA. Nevertheless, LPS Oag does not affect IcsA_{WT} biogenesis but affects
560 biogenesis of IcsA that has mutational alteration in the AC region, which is a novel finding
561 that has never been reported before in IcsA or other autotransporters. As suggested
562 above, we speculate that LPS, Skp and SurA interaction with IcsA may be altered by the

563 AC region mutations, and this remains to be investigated. Collectively, our data suggest an
564 alternative role for the AC domain and that it affects interactions with chaperones during
565 export. Our findings provide new insights into lcsA biogenesis. In addition, we have
566 identified a new N-WASP binding/interaction site within the AC region which narrows down
567 the previously reported N-WASP interacting region (aa 508-730) (May & Morona, 2008)
568 and this is the subject of further study (Teh and Morona, unpublished data).

569 **Acknowledgements**

570 We thank Prof. Thomas Silhavy (Princeton University) for the anti-Skp antibody and Δskp
571 *zae::Tn10* mutant, Prof. Carol Gross (UCSF) for the anti-SurA antibody and *surA::Km*
572 mutant, Prof. Michael Ehrmann (University of Duisburg-Essen) for the anti-MBP-DegP
573 antibody. This work is supported by a Program Grant from the National Health and Medical
574 Research Council (NHMRC) of Australia. M.Y.T was the recipient of a Faculty of Science
575 Postgraduate Scholarship from the University of Adelaide.

576 **References**

- 577 **Alexander, D. C. & Valvano, M. A. (1994).** Role of the *rfe* gene in the biosynthesis of the
578 *Escherichia coli* O7-specific lipopolysaccharide and other O-specific polysaccharides
579 containing N-acetylglucosamine. *J Bacteriol* **176**, 7079-7084.
580
- 581 **Baker, S. J., Gunn, J. S. & Morona, R. (1999).** The *Salmonella typhi* melittin resistance gene
582 *pqaB* affects intracellular growth in PMA-differentiated U937 cells, polymyxin B resistance
583 and lipopolysaccharide. *Microbiology* **145 (Pt 2)**, 367-378.
584
- 585 **Bartolome, B., Jubete, Y., Martinez, E. & de la Cruz, F. (1991).** Construction and properties
586 of a family of pACYC184-derived cloning vectors compatible with pBR322 and its derivatives.
587 *Gene* **102**, 75-78.
588
- 589 **Bernardini, M. L., Mounier, J., d'Hauteville, H., Coquis-Rondon, M. & Sansonetti, P. J.**
590 **(1989).** Identification of *icsA*, a plasmid locus of *Shigella flexneri* that governs bacterial intra-
591 and intercellular spread through interaction with F-actin. *Proc Natl Acad Sci U S A* **86**, 3867-
592 3871.
593
- 594 **Bitto, E. & McKay, D. B. (2003).** The periplasmic molecular chaperone protein SurA binds a
595 peptide motif that is characteristic of integral outer membrane proteins. *J Biol Chem* **278**,
596 49316-49322.
597
- 598 **Bolivar, F., Rodriguez, R. L., Betlach, M. C. & Boyer, H. W. (1977).** Construction and
599 characterization of new cloning vehicles. I. Ampicillin-resistant derivatives of the plasmid
600 pMB9. *Gene* **2**, 75-93.
601
- 602 **Brandish, P. E., Kimura, K. I., Inukai, M., Southgate, R., Lonsdale, J. T. & Bugg, T. D.**
603 **(1996).** Modes of action of tunicamycin, liposidomycin B, and mureidomycin A: inhibition of
604 phospho-N-acetylmuramyl-pentapeptide translocase from *Escherichia coli*. *Antimicrob Agents*
605 *Chemother* **40**, 1640-1644.
606
- 607 **Brandon, L. D. & Goldberg, M. B. (2001).** Periplasmic transit and disulfide bond formation of
608 the autotransported *Shigella* protein IcsA. *J Bacteriol* **183**, 951-958.
609
- 610 **Brandon, L. D., Goehring, N., Janakiraman, A., Yan, A. W., Wu, T., Beckwith, J. & Goldberg,**
611 **M. B. (2003).** IcsA, a polarly localized autotransporter with an atypical signal peptide, uses
612 the Sec apparatus for secretion, although the Sec apparatus is circumferentially distributed.
613 *Mol Microbiol* **50**, 45-60.
614
- 615 **d'Hauteville, H., Dufourcq Lagelouse, R., Nato, F. & Sansonetti, P. J. (1996).** Lack of
616 cleavage of IcsA in *Shigella flexneri* causes aberrant movement and allows demonstration of a
617 cross-reactive eukaryotic protein. *Infect Immun* **64**, 511-517.
618
- 619 **Davison, J., Heusterspreute, M., Chevalier, N., Ha-Thi, V. & Brunel, F. (1987).** Vectors with
620 restriction site banks. V. pJRD215, a wide-host-range cosmid vector with multiple cloning
621 sites. *Gene* **51**, 275-280.
622
- 623 **Duguay, A. R. & Silhavy, T. J. (2004).** Quality control in the bacterial periplasm. *Biochim*
624 *Biophys Acta* **1694**, 121-134.
625

626 **Emsley, P., Charles, I. G., Fairweather, N. F. & Isaacs, N. W. (1996).** Structure of *Bordetella*
627 *pertussis* virulence factor P.69 pertactin. *Nature* **381**, 90-92.
628

629 **Fukuda, I., Suzuki, T., Munakata, H., Hayashi, N., Katayama, E., Yoshikawa, M. &**
630 **Sasakawa, C. (1995).** Cleavage of *Shigella* surface protein VirG occurs at a specific site, but
631 the secretion is not essential for intracellular spreading. *J Bacteriol* **177**, 1719-1726.
632

633 **Goldberg, M. B., Barzu, O., Parsot, C. & Sansonetti, P. J. (1993).** Unipolar localization and
634 ATPase activity of IcsA, a *Shigella flexneri* protein involved in intracellular movement. *Infect*
635 *Agents Dis* **2**, 210-211.
636

637 **Goldberg, M. B. (2001).** Actin-based motility of intracellular microbial pathogens. *Microbiol*
638 *Mol Biol Rev* **65**, 595-626, table of contents.
639

640 **Guzman, L. M., Belin, D., Carson, M. J. & Beckwith, J. (1995).** Tight regulation, modulation,
641 and high-level expression by vectors containing the arabinose PBAD promoter. *J Bacteriol*
642 **177**, 4121-4130.
643

644 **Henderson, I. R., Navarro-Garcia, F., Desvaux, M., Fernandez, R. C. & Ala'Aldeen, D.**
645 **(2004).** Type V protein secretion pathway: the autotransporter story. *Microbiol Mol Biol Rev*
646 **68**, 692-744.
647

648 **Ieva, R. & Bernstein, H. D. (2009).** Interaction of an autotransporter passenger domain with
649 BamA during its translocation across the bacterial outer membrane. *Proc Natl Acad Sci U S A*
650 **106**, 19120-19125.
651

652 **Ieva, R., Tian, P., Peterson, J. H. & Bernstein, H. D. (2011).** Sequential and spatially
653 restricted interactions of assembly factors with an autotransporter beta domain. *Proc Natl*
654 *Acad Sci U S A* **108**, E383-391.
655

656 **Jain, S. & Goldberg, M. B. (2007).** Requirement for YaeT in the outer membrane assembly of
657 autotransporter proteins. *J Bacteriol* **189**, 5393-5398.
658

659 **Johnson, T. A., Qiu, J., Plaut, A. G. & Holyoak, T. (2009).** Active-site gating regulates
660 substrate selectivity in a chymotrypsin-like serine protease the structure of *Haemophilus*
661 *influenzae* immunoglobulin A1 protease. *J Mol Biol* **389**, 559-574.
662

663 **Khan, S., Mian, H. S., Sandercock, L. E., Chirgadze, N. Y. & Pai, E. F. (2011).** Crystal
664 structure of the passenger domain of the *Escherichia coli* autotransporter EspP. *J Mol Biol* **413**,
665 985-1000.
666

667 **Klemm, P., Vejborg, R. M. & Sherlock, O. (2006).** Self-associating autotransporters, SAATs:
668 functional and structural similarities. *Int J Med Microbiol* **296**, 187-195.
669

670 **Kokotek, W. & Lotz, W. (1989).** Construction of a lacZ-kanamycin-resistance cassette, useful
671 for site-directed mutagenesis and as a promoter probe. *Gene* **84**, 467-471.
672

673 **Kolmar, H., Waller, P. R. & Sauer, R. T. (1996).** The DegP and DegQ periplasmic
674 endoproteases of *Escherichia coli*: specificity for cleavage sites and substrate conformation. *J*
675 *Bacteriol* **178**, 5925-5929.
676

677 **Korndorfer, I. P., Dommel, M. K. & Skerra, A. (2004).** Structure of the periplasmic
678 chaperone Skp suggests functional similarity with cytosolic chaperones despite differing
679 architecture. *Nat Struct Mol Biol* **11**, 1015-1020.
680

681 **Kuhnel, K. & Diezmann, D. (2011).** Crystal structure of the autochaperone region from the
682 *Shigella flexneri* autotransporter IcsA. *J Bacteriol* **193**, 2042-2045.
683

684 **Lett, M. C., Sasakawa, C., Okada, N., Sakai, T., Makino, S., Yamada, M., Komatsu, K. &**
685 **Yoshikawa, M. (1989).** *virG*, a plasmid-coded virulence gene of *Shigella flexneri*:
686 identification of the *virG* protein and determination of the complete coding sequence. *J*
687 *Bacteriol* **171**, 353-359.
688

689 **Lugtenberg, B., Meijers, J., Peters, R., van der Hoek, P. & van Alphen, L. (1975).**
690 Electrophoretic resolution of the "major outer membrane protein" of *Escherichia coli* K12 into
691 four bands. *FEBS Lett* **58**, 254-258.
692

693 **Makino, S., Sasakawa, C., Kamata, K., Kurata, T. & Yoshikawa, M. (1986).** A genetic
694 determinant required for continuous reinfection of adjacent cells on large plasmid in *S.*
695 *flexneri* 2a. *Cell* **46**, 551-555.
696

697 **May, K. L. & Morona, R. (2008).** Mutagenesis of the *Shigella flexneri* autotransporter IcsA
698 reveals novel functional regions involved in IcsA biogenesis and recruitment of host neural
699 Wiscott-Aldrich syndrome protein. *J Bacteriol* **190**, 4666-4676.
700

701 **May, K. L., Grabowicz, M., Polyak, S. W. & Morona, R. (2012).** Self-association of the
702 *Shigella flexneri* IcsA autotransporter protein. *Microbiology* **158**, 1874-1883.
703

704 **Meng, G., Spahich, N., Kenjale, R., Waksman, G. & St Geme, J. W., 3rd (2011).** Crystal
705 structure of the *Haemophilus influenzae* Hap adhesin reveals an intercellular oligomerization
706 mechanism for bacterial aggregation. *EMBO J* **30**, 3864-3874.
707

708 **Miller, J. (1972).** Experiments in molecular genetics. *Cold Spring Harbor Laboratory Press,*
709 *Cold Spring Harbor, NY.*
710

711 **Morona, R., Mavris, M., Fallarino, A. & Manning, P. A. (1994).** Characterization of the *rfc*
712 region of *Shigella flexneri*. *J Bacteriol* **176**, 733-747.
713

714 **Morona, R., van den Bosch, L. & Manning, P. A. (1995).** Molecular, genetic, and topological
715 characterization of O-antigen chain length regulation in *Shigella flexneri*. *J Bacteriol* **177**,
716 1059-1068.
717

718 **Morona, R., Daniels, C. & Van Den Bosch, L. (2003).** Genetic modulation of *Shigella flexneri*
719 2a lipopolysaccharide O antigen modal chain length reveals that it has been optimized for
720 virulence. *Microbiology* **149**, 925-939.
721

722 **Morona, R. & Van Den Bosch, L. (2003).** Lipopolysaccharide O antigen chains mask IcsA
723 (VirG) in *Shigella flexneri*. *FEMS Microbiol Lett* **221**, 173-180.
724

725 **Murray, G. L., Attridge, S. R. & Morona, R. (2003).** Regulation of *Salmonella typhimurium*
726 lipopolysaccharide O antigen chain length is required for virulence; identification of FepE as a
727 second Wzz. *Mol Microbiol* **47**, 1395-1406.

728
729 **Mutalik, V. K., Nonaka, G., Ades, S. E., Rhodius, V. A. & Gross, C. A. (2009).** Promoter
730 strength properties of the complete sigma E regulon of *Escherichia coli* and *Salmonella*
731 *enterica*. *J Bacteriol* **191**, 7279-7287.
732
733 **Narita, S. & Tokuda, H. (2009).** Biochemical characterization of an ABC transporter LptBFGC
734 complex required for the outer membrane sorting of lipopolysaccharides. *FEBS Lett* **583**,
735 2160-2164.
736
737 **Oliver, D. C., Huang, G. & Fernandez, R. C. (2003a).** Identification of secretion determinants
738 of the *Bordetella pertussis* BrkA autotransporter. *J Bacteriol* **185**, 489-495.
739
740 **Oliver, D. C., Huang, G., Nodel, E., Pleasance, S. & Fernandez, R. C. (2003b).** A conserved
741 region within the *Bordetella pertussis* autotransporter BrkA is necessary for folding of its
742 passenger domain. *Mol Microbiol* **47**, 1367-1383.
743
744 **Otto, B. R., Sijbrandi, R., Luirink, J., Oudega, B., Heddle, J. G., Mizutani, K., Park, S. Y. &**
745 **Tame, J. R. (2005).** Crystal structure of hemoglobin protease, a heme binding
746 autotransporter protein from pathogenic *Escherichia coli*. *J Biol Chem* **280**, 17339-17345.
747
748 **Pallen, M. J., Chaudhuri, R. R. & Henderson, I. R. (2003).** Genomic analysis of secretion
749 systems. *Curr Opin Microbiol* **6**, 519-527.
750
751 **Papadopoulos, M. & Morona, R. (2010).** Mutagenesis and chemical cross-linking suggest
752 that Wzz dimer stability and oligomerization affect lipopolysaccharide O-antigen modal chain
753 length control. *J Bacteriol* **192**, 3385-3393.
754
755 **Peterson, J. H., Tian, P., Ieva, R., Dautin, N. & Bernstein, H. D. (2010).** Secretion of a
756 bacterial virulence factor is driven by the folding of a C-terminal segment. *Proc Natl Acad Sci U*
757 *SA* **107**, 17739-17744.
758
759 **Philpott, D. J., Edgeworth, J. D. & Sansonetti, P. J. (2000).** The pathogenesis of *Shigella*
760 *flexneri* infection: lessons from in vitro and in vivo studies. *Philos Trans R Soc Lond B Biol Sci*
761 **355**, 575-586.
762
763 **Purdy, G. E., Hong, M. & Payne, S. M. (2002).** *Shigella flexneri* DegP facilitates IcsA surface
764 expression and is required for efficient intercellular spread. *Infect Immun* **70**, 6355-6364.
765
766 **Purdy, G. E., Fisher, C. R. & Payne, S. M. (2007).** IcsA surface presentation in *Shigella flexneri*
767 requires the periplasmic chaperones DegP, Skp, and SurA. *J Bacteriol* **189**, 5566-5573.
768
769 **Purins, L., Van Den Bosch, L., Richardson, V. & Morona, R. (2008).** Coiled-coil regions play
770 a role in the function of the *Shigella flexneri* O-antigen chain length regulator WzzpHS2.
771 *Microbiology* **154**, 1104-1116.
772
773 **Raetz, C. R. & Whitfield, C. (2002).** Lipopolysaccharide endotoxins. *Annu Rev Biochem* **71**,
774 635-700.
775
776 **Raivio, T. L. & Silhavy, T. J. (2001).** Periplasmic stress and ECF sigma factors. *Annu Rev*
777 *Microbiol* **55**, 591-624.
778

779 **Reeves, P. R., Hobbs, M., Valvano, M. A. & other authors (1996).** Bacterial polysaccharide
780 synthesis and gene nomenclature. *Trends Microbiol* **4**, 495-503.
781

782 **Rhodus, V. A., Suh, W. C., Nonaka, G., West, J. & Gross, C. A. (2006).** Conserved and
783 variable functions of the sigmaE stress response in related genomes. *PLoS Biol* **4**, e2.
784

785 **Robbins, J. R., Monack, D., McCallum, S. J., Vegas, A., Pham, E., Goldberg, M. B. & Theriot,
786 J. A. (2001).** The making of a gradient: IcsA (VirG) polarity in *Shigella flexneri*. *Mol Microbiol*
787 **41**, 861-872.
788

789 **Ruiz-Perez, F., Henderson, I. R., Leyton, D. L., Rossiter, A. E., Zhang, Y. & Nataro, J. P.
790 (2009).** Roles of periplasmic chaperone proteins in the biogenesis of serine protease
791 autotransporters of *Enterobacteriaceae*. *J Bacteriol* **191**, 6571-6583.
792

793 **Ruiz-Perez, F., Henderson, I. R. & Nataro, J. P. (2010).** Interaction of FkpA, a peptidyl-prolyl
794 cis/trans isomerase with EspP autotransporter protein. *Gut Microbes* **1**, 339-344.
795

796 **Ruiz, N., Gronenberg, L. S., Kahne, D. & Silhavy, T. J. (2008).** Identification of two inner-
797 membrane proteins required for the transport of lipopolysaccharide to the outer membrane
798 of *Escherichia coli*. *Proc Natl Acad Sci U S A* **105**, 5537-5542.
799

800 **Ruiz, N., Kahne, D. & Silhavy, T. J. (2009).** Transport of lipopolysaccharide across the cell
801 envelope: the long road of discovery. *Nat Rev Microbiol* **7**, 677-683.
802

803 **Sandlin, R. C., Lampel, K. A., Keasler, S. P., Goldberg, M. B., Stolzer, A. L. & Maurelli, A. T.
804 (1995).** Avirulence of rough mutants of *Shigella flexneri*: requirement of O antigen for correct
805 unipolar localization of IcsA in the bacterial outer membrane. *Infect Immun* **63**, 229-237.
806

807 **Sansonetti, P. J., Arondel, J., Fontaine, A., d'Hauteville, H. & Bernardini, M. L. (1991).**
808 OmpB (osmo-regulation) and *icsA* (cell-to-cell spread) mutants of *Shigella flexneri*: vaccine
809 candidates and probes to study the pathogenesis of shigellosis. *Vaccine* **9**, 416-422.
810

811 **Sauri, A., Soprova, Z., Wickstrom, D., de Gier, J. W., Van der Schors, R. C., Smit, A. B., Jong,
812 W. S. & Luirink, J. (2009).** The Bam (Omp85) complex is involved in secretion of the
813 autotransporter haemoglobin protease. *Microbiology* **155**, 3982-3991.
814

815 **Sklar, J. G., Wu, T., Kahne, D. & Silhavy, T. J. (2007).** Defining the roles of the periplasmic
816 chaperones SurA, Skp, and DegP in *Escherichia coli*. *Genes Dev* **21**, 2473-2484.
817

818 **Soprova, Z., Sauri, A., van Ulsen, P., Tame, J. R., den Blaauwen, T., Jong, W. S. & Luirink, J.
819 (2010).** A conserved aromatic residue in the autochaperone domain of the autotransporter
820 Hbp is critical for initiation of outer membrane translocation. *J Biol Chem* **285**, 38224-38233.
821

822 **Sperandeo, P., Lau, F. K., Carpentieri, A., De Castro, C., Molinaro, A., Deho, G., Silhavy, T. J.
823 & Polissi, A. (2008).** Functional analysis of the protein machinery required for transport of
824 lipopolysaccharide to the outer membrane of *Escherichia coli*. *J Bacteriol* **190**, 4460-4469.
825

826 **Spieß, C., Beil, A. & Ehrmann, M. (1999).** A temperature-dependent switch from chaperone
827 to protease in a widely conserved heat shock protein. *Cell* **97**, 339-347.
828

829 **Steinbacher, S., Baxa, U., Miller, S., Weintraub, A., Seckler, R. & Huber, R. (1996).** Crystal
830 structure of phage P22 tailspike protein complexed with *Salmonella* sp. O-antigen receptors.
831 *Proc Natl Acad Sci U S A* **93**, 10584-10588.
832

833 **Steinhauer, J., Agha, R., Pham, T., Varga, A. W. & Goldberg, M. B. (1999).** The unipolar
834 *Shigella* surface protein IcsA is targeted directly to the bacterial old pole: IcsP cleavage of IcsA
835 occurs over the entire bacterial surface. *Mol Microbiol* **32**, 367-377.
836

837 **Suzuki, T., Lett, M. C. & Sasakawa, C. (1995).** Extracellular transport of VirG protein in
838 *Shigella*. *J Biol Chem* **270**, 30874-30880.
839

840 **Suzuki, T. & Sasakawa, C. (2001).** Molecular basis of the intracellular spreading of *Shigella*.
841 *Infect Immun* **69**, 5959-5966.
842

843 **Tran, A. X., Dong, C. & Whitfield, C. (2010).** Structure and functional analysis of LptC, a
844 conserved membrane protein involved in the lipopolysaccharide export pathway in
845 *Escherichia coli*. *J Biol Chem* **285**, 33529-33539.
846

847 **Tsai, C. M. & Frasch, C. E. (1982).** A sensitive silver stain for detecting lipopolysaccharides in
848 polyacrylamide gels. *Anal Biochem* **119**, 115-119.
849

850 **Vaara, M. & Vaara, T. (1983).** Sensitization of Gram-negative bacteria to antibiotics and
851 complement by a nontoxic oligopeptide. *Nature* **303**, 526-528.
852

853 **Vaara, M. (1992).** Agents that increase the permeability of the outer membrane. *Microbiol*
854 *Rev* **56**, 395-411.
855

856 **Van Den Bosch, L., Manning, P. A. & Morona, R. (1997).** Regulation of O-antigen chain
857 length is required for *Shigella flexneri* virulence. *Mol Microbiol* **23**, 765-775.
858

859 **Van Den Bosch, L. & Morona, R. (2003).** The actin-based motility defect of a *Shigella flexneri*
860 *rmlD* rough LPS mutant is not due to loss of IcsA polarity. *Microb Pathog* **35**, 11-18.
861

862 **Wagner, J. K., Heindl, J. E., Gray, A. N., Jain, S. & Goldberg, M. B. (2009).** Contribution of the
863 periplasmic chaperone Skp to efficient presentation of the autotransporter IcsA on the surface
864 of *Shigella flexneri*. *J Bacteriol* **191**, 815-821.
865

866 **Walton, T. A. & Sousa, M. C. (2004).** Crystal structure of Skp, a prefoldin-like chaperone that
867 protects soluble and membrane proteins from aggregation. *Mol Cell* **15**, 367-374.
868

869 **Walton, T. A., Sandoval, C. M., Fowler, C. A., Pardi, A. & Sousa, M. C. (2009).** The cavity-
870 chaperone Skp protects its substrate from aggregation but allows independent folding of
871 substrate domains. *Proc Natl Acad Sci U S A* **106**, 1772-1777.
872

873 **Wells, T. J., Totsika, M. & Schembri, M. A. (2010).** Autotransporters of *Escherichia coli*: a
874 sequence-based characterization. *Microbiology* **156**, 2459-2469.
875

876 **Xu, X., Wang, S., Hu, Y. X. & McKay, D. B. (2007).** The periplasmic bacterial molecular
877 chaperone SurA adapts its structure to bind peptides in different conformations to assert a
878 sequence preference for aromatic residues. *J Mol Biol* **373**, 367-381.
879

880 **Yen, Y. T., Kostakioti, M., Henderson, I. R. & Stathopoulos, C. (2008).** Common themes and
881 variations in serine protease autotransporters. *Trends Microbiol* **16**, 370-379.

882

883 **Zalucki, Y. M. & Jennings, M. P. (2007).** Experimental confirmation of a key role for non-
884 optimal codons in protein export. *Biochem Biophys Res Commun* **355**, 143-148.

885

886

887

887 **Table 1: Bacterial strains and plasmids**

| Strain or plasmid | Relevant characteristics # | Reference or source |
|----------------------------|--|--------------------------------|
| <i>E. coli</i> K-12 | | |
| DH5 α | <i>F</i> -(80 <i>dlacZ</i> M15) (<i>lacZYA-argF</i>) U169 <i>hsdR17</i> (<i>r-m+</i>) <i>recA1 endA1 relA1 deoR</i> | Gibco-BRL |
| DH5 | <i>F</i> -, <i>rec A1</i> , <i>end A1</i> , <i>hod R17</i> (<i>rk</i> -, <i>mk</i> +), <i>sup E44</i> , <i>lambda</i> -, <i>thi 1</i> , <i>gyrA</i> , <i>rel A1</i> | Laboratory collection |
| M15 | Nal ^s Str ^s Rif ^s <i>thi</i> ⁻ <i>lac</i> ⁻ <i>ara</i> ⁺ <i>gal</i> ⁺ <i>mtf</i> <i>F</i> <i>recA</i> ⁺ <i>uvr</i> ⁺ <i>lon</i> ⁺ | Qiagen |
| S-17 | Conjugative strain | Laboratory collection |
| RMA2802 | S-17-1 λ <i>pir</i> [pCVD442 + <i>degP</i> ::Cm] | (Purins <i>et al.</i> , 2008) |
| MC4100 | <i>F-araD139 A</i> (<i>argF-lac</i>)U169 <i>rpsL150 deoCI relAI</i> <i>thiA ptsF25 flbB5301</i> | (Zalucki & Jennings, 2007) |
| JGS190 | MC4100 <i>ara</i> ⁺ Δ <i>skp</i> <i>zae</i> :: <i>Tn10</i> | (Sklar <i>et al.</i> , 2007) |
| MG1655 | K-12 (MG1655) <i>rph</i> -1 | (Mutalik <i>et al.</i> , 2009) |
| CAG41291 | MG1655 <i>surA</i> ::Km ^R | Carol Gross |
| <i>S. flexneri</i> | | |
| 2457T | <i>S. flexneri</i> 2a wild type | Laboratory collection |
| RMA2041 | 2457T Δ <i>icsA</i> ::Tc ^R | (Van Den Bosch & Morona, 2003) |
| RMA2090 | RMA2041 [plcsA] | (Van Den Bosch & Morona, 2003) |
| RMA2043 | RMA2041 Δ <i>rmID</i> ::Km ^R | (Van Den Bosch & Morona, 2003) |
| RMA2107 | RMA2043 [plcsA] | (Van Den Bosch & Morona, 2003) |
| RMA2159 | Virulence plasmid-cured 2457T | Laboratory collection |
| RMA2161 | RMA2159 <i>rfbD</i> ::Km ^R | Laboratory collection |
| KMRM109 | RMA2041 [plcsA _{i633}] | (May & Morona, 2008) |
| KMRM114 | RMA2041 [plcsA _{i643}] | (May & Morona, 2008) |
| KMRM134 | RMA2041 [plcsA _{i677}] | (May & Morona, 2008) |
| KMRM147 | RMA2041 [plcsA _{i716}] | (May & Morona, 2008) |
| MYRM275 | RMA2043 [plcsA _{i643}] | This study |
| MYRM276 | RMA2043 [plcsA _{i677}] | This study |
| MYRM277 | RMA2043 [plcsA _{i716}] | This study |
| MYRM289 | RMA2043 [plcsA _{i633}] | This study |
| MYRM293 | RMA2041 [pBR322] | This study |
| MYRM294 | RMA2043 [pBR322] | This study |
| MYRM296 | RMA2159 [pBAD33::icsP] | This study |
| MYRM297 | RMA2161 [pBAD33::icsP] | This study |
| MYRM298 | MYRM296 [plcsA] | This study |
| MYRM299 | MYRM297 [plcsA] | This study |
| MYRM303 | MYRM296 [plcsA _{i633}] | This study |
| MYRM304 | MYRM296 [plcsA _{i643}] | This study |
| MYRM305 | MYRM296 [plcsA _{i677}] | This study |
| MYRM306 | MYRM296 [plcsA _{i716}] | This study |
| MYRM310 | MYRM297 [plcsA _{i633}] | This study |
| MYRM311 | MYRM297 [plcsA _{i643}] | This study |
| MYRM312 | MYRM297 [plcsA _{i677}] | This study |
| MYRM313 | MYRM297 [plcsA _{i716}] | This study |
| MYRM373 | UT5600 [pJRD215 + plcsA] | This study |
| MYRM374 | UT5600 [pJRD215 + pBR322] | This study |
| MYRM378 | UT5600 [pJRD215 + plcsA _{i633}] | This study |
| MYRM379 | UT5600 [pJRD215 + plcsA _{i643}] | This study |

| | | |
|-----------------------|---|---|
| MYRM380 | UT5600 [pJRD215 + plcsA _{i677}] | This study |
| MYRM381 | UT5600 [pJRD215 + plcsA _{i716}] | This study |
| MYRM578 | UT5600 [pRMA154 + plcsA] | This study |
| MYRM383 | UT5600 [pRMA154 + pBR322] | This study |
| MYRM387 | UT5600 [pRMA154 + plcsA _{i633}] | This study |
| MYRM388 | UT5600 [pRMA154 + plcsA _{i643}] | This study |
| MYRM389 | UT5600 [pRMA154 + plcsA _{i677}] | This study |
| MYRM390 | UT5600 [pRMA154 + plcsA _{i716}] | This study |
| MYRM522 | RMA2041 <i>degP</i> ::Cm ^R | This study |
| MYRM675 | MYRM522 [plcsA] | This study |
| MYRM525 | MYRM522 [plcsA _{i716}] | This study |
| MYRM526 | MYRM522 [pBR322] | This study |
| MYRM734 | RMA2090 [pMYRM718] | This study |
| MYRM721 | RMA2107 [pMYRM718] | This study |
| MYRM722 | KMRM147 [pMYRM718] | This study |
| MYRM723 | MYRM277 [pMYRM718] | This study |
| MYRM724 | RMA2107 [pACYC184] | This study |
| MYRM725 | MYRM289 [pACYC184] | This study |
| MYRM726 | MYRM275 [pACYC184] | This study |
| MYRM727 | MYRM276 [pACYC184] | This study |
| MYRM728 | MYRM277 [pACYC184] | This study |
| MYRM729 | RMA2107 [pRMA727] | This study |
| MYRM730 | MYRM289 [pRMA727] | This study |
| MYRM731 | MYRM275 [pRMA727] | This study |
| MYRM732 | MYRM276 [pRMA727] | This study |
| MYRM733 | MYRM277 [pRMA727] | This study |
| Plasmids | | |
| pACYC184 | Low copy number; P15A <i>ori</i> ; Tc ^R , Cm ^R | NEB |
| pBAD33 | Arabinose-inducible pBAD promoter vector; Cm ^R | (Guzman <i>et al.</i> , 1995) |
| pBAD33:: <i>icsP</i> | <i>icsP</i> gene cloned into pBAD33; Cm ^R | This study |
| pBR322 | Medium copy no.; ColE1 <i>ori</i> ; Ap ^R , Tc ^R | (Bolivar <i>et al.</i> , 1977) |
| plcsA | <i>icsA</i> gene cloned into pBR322; Ap ^R | (Van Den Bosch & Morona, 2003) |
| plcsA _{i633} | plcsA with 5 amino acids insertion at aa633; Ap ^R | (May & Morona, 2008) |
| plcsA _{i643} | plcsA with 5 amino acids insertion at aa643; Ap ^R | (May & Morona, 2008) |
| plcsA _{i677} | plcsA with 5 amino acids insertion at aa677; Ap ^R | (May & Morona, 2008) |
| plcsA _{i716} | plcsA with 5 amino acids insertion at aa716; Ap ^R | (May & Morona, 2008) |
| pJRD215 | Broad-host-range cosmid cloning vector; Km ^R , Sm ^R ; <i>mob</i> , plasmid mobilisation functions | (Davison <i>et al.</i> , 1987) |
| pRMA154 | pJRD215 _{ClaI-Kpn1} -pPM2213 _{ClaI-Kpn1} Km ^R , Sm ^R ; encodes <i>galF</i> , <i>rfb</i> locus, <i>rfc</i> and <i>gnd</i> , Oag biosynthesis genes from <i>S. flexneri</i> | (Morona <i>et al.</i> , 1994) |
| pKOK6.1 | Derivative of pKOK6 with inverse direction of the <i>lacZ</i> /Kan cassette in pKOK6 and has additional stop codons inserted into upstream of <i>lacZ</i> via the <i>Bam</i> HI site; Cm ^R , Km ^R | (Kokotek & Lotz, 1989; Murray <i>et al.</i> , 2003) |
| pQE60 | Expression vector with a C-terminal His ₆ tag; Ap ^R | Qiagen |
| pQE60:: <i>icsP</i> | <i>icsP</i> gene cloned into pQE60; Ap ^R | This study |
| pRMA727 | <i>rmlD</i> (<i>rfbD</i>) gene cloned into pACYC184; Cm ^R | (Van Den Bosch <i>et al.</i> , 1997) |
| pSU23 | Medium copy no.; P15A <i>ori</i> ; Cm ^R | (Bartolome <i>et al.</i> , 1991) |
| pMYRM632 | <i>icsA</i> promoter region transcriptionally fused to <i>lacZ</i> -Km; Ap ^R , Cm ^R , Km ^R | This study |
| pMYRM676 | Derived from pMYRM632 with a stop codon inserted between <i>icsA</i> and <i>lacZ</i> ; Ap ^R , Cm ^R , Km ^R | This study |
| pMYRM718 | <i>Pst</i> I- <i>Sal</i> I fragment containing <i>icsA</i> promoter-TGA- | This study |

lacZ-Km derived from pMYRM676, cloned into
pSU23; Cm^R, Km^R

888 # Tc^R, Tetracycline resistant; Km^R, Kanamycin resistant; Ap^R, Ampicillin resistant; Cm^R, Chloramphenicol
889 resistant; Sm^R, Streptomycin resistant.

890

891 **Figure Legends**

892 **Figure 1. *IcsA_i* expression and localisation in S-LPS and R-LPS *S. flexneri*.** (a) Whole
893 cell lysates from mid-exponential phase cultures of the indicated *S. flexneri* strains were
894 subjected to Western immunoblotting with anti-IcsA antibody. S= S-LPS; R = R-LPS. IcsA⁻
895 = IcsA deletion control. The 120 kDa band corresponds to the full length IcsA and the 85
896 kDa band corresponds to the cleaved form (IcsA'). (b) IF microscopy to detect IcsA_{WT} or
897 IcsA_i surface distribution. Mid-exponential phase cultures of the indicated *S. flexneri*
898 strains were formalin fixed and labelled with anti-IcsA antibody and then goat anti-rabbit
899 Alexa Fluor-488 secondary antibody. The white arrow indicates S-LPS *S. flexneri*
900 expressing low levels of IcsA_{i716} (KM147). Scale bar = 10 µm.

901

902 **Figure 2. *rmID* complemented *S. flexneri* strains expressing IcsA_{WT} or IcsA_i.** Whole
903 cell lysates from mid-exponential phase cultures of indicated the *S. flexneri* strains were
904 prepared as described in the Methods. (a) LPS samples (equivalent to 1 x 10⁹ bacteria)
905 were prepared, electrophoresed on a SDS-15%-PAGE gel and silver stained as described
906 in the Methods. (b) Whole cell lysates were electrophoresed on a SDS-12%-PAGE gel and
907 subjected to Western immunoblotting with anti-IcsA antibody.

908

909 **Figure 3. LPS depletion-regeneration assay.** Mid-exponential phase S-LPS *S. flexneri*
910 expressing IcsA_{WT} or IcsA_{i716} were treated with 10 µg tunicamycin mL⁻¹ or DMSO and 3 µg
911 polymyxin B nonapeptide mL⁻¹ (PMBN) for 3 h at 37°C, followed by removal of
912 tunicamycin/PMBN/DMSO and allowed to grow for another 3 h to regenerate LPS Oag as
913 described in the Methods. (a) LPS samples (equivalent to 1 x 10⁹ bacteria) were prepared,
914 electrophoresed on a SDS-15%-PAGE gel and silver stained as described in the Methods.
915 U = Untreated; D = Degeneration phase; R = Regeneration phase. (b) Whole cell lysates

916 were electrophoresed on a SDS-12%-PAGE gel, and subjected to Western
917 immunoblotting with anti-IcsA antibody.

918

919 **Figure 4. Effect of IcsP on IcsA_i production levels.** (a) Trichloroacetic acid-
920 precipitated culture supernatants from mid-exponential phase cultures of the indicated *S.*
921 *flexneri* strains. P = Whole cell lysates; SN = Supernatant. (b, c) Mid-exponential phase
922 cultures of the indicated *S. flexneri* strain expressing IcsA_{WT} or IcsA_i mutants were treated
923 with 0.2% (w/v) L-arabinose to induce IcsP expression as described in the Methods.
924 Whole cell lysates were prepared, electrophoresed on a SDS-12%-PAGE gel and
925 subjected to Western immunoblotting with anti-IcsA and anti-IcsP. (b) Western blot
926 analysis of IcsA_i mutant and IcsP expression in virulence plasmid-cured S-LPS strain. (c)
927 Western blot analysis of IcsA_i mutant and IcsP expression in virulence plasmid-cured R-
928 LPS strain. The positions of the bands corresponding to IcsA, IcsA_i and IcsP are shown.

929

930 **Figure 5. β-galactosidase assay on S-LPS and R-LPS *S. flexneri* strains.** S-LPS and
931 R-LPS *S. flexneri* strains expressing IcsA_{WT}, S-LPS and R-LPS *S. flexneri* strains
932 expressing IcsA_{i716} that are carrying pSU23-*PicsA*-TGA-*lacZ* were grown to mid-
933 exponential phase at 37°C and the β-galactosidase activity was measured as described in
934 the Methods. Data represent the means of three independent experiments. Error bars
935 represent standard error of the mean (**P* < 0.05). S-LPS IcsA_{WT} = MYRM734; R-LPS
936 IcsA_{WT} = MYRM721; S-LPS IcsA_{i716} = MYRM722; R-LPS IcsA_{i716} = MYRM723.

937

938 **Figure 6. IcsA production in *S. flexneri* *degP*::Cm Δ*icsA*.** Whole cell lysates from mid-
939 exponential phase cultures (grown at 30°C or 37°C) of the indicated *S. flexneri* strains

940 were electrophoresed on a SDS-12%-PAGE gel and subjected to Western immunoblotting
941 with anti-IcsA antibody.

942

943 **Figure 7. N-WASP recruitment and F-actin comet tail formation by intracellular S-**
944 **LPS and R-LPS *S. flexneri* strains.** HeLa cells infected with *S. flexneri* expressing
945 IcsA_{WT}, IcsA_{i677} or IcsA_{i716} were labelled with anti-N-WASP and Alexa Fluor 594-
946 conjugated donkey anti-rabbit secondary antibody (red) to detect N-WASP, F-actin was
947 labelled with Alexa Fluor 488-phalloidin (green), HeLa cells and bacteria was labelled with
948 DAPI (blue) as described in the Methods. Strains were assessed in two independent
949 experiments. Arrows indicate N-WASP recruitment and F-actin comet tail formation. Insert
950 shows an enlarged view for greater clarity. Scale bar = 10 µm.


951

952 **Figure 8. Trypsin accessibility of IcsA_i mutants.** Mid-exponential phase cultures of the
953 indicated R-LPS *S. flexneri* strains expressing IcsA_{WT} or IcsA_i mutants were treated with
954 0.1 µg trypsin mL⁻¹ at 25°C. Aliquots were taken at 0 min, 5 min, 15 min and 20 min and
955 supplemented with 1 mM phenylmethylsulphonylfluoride (PMSF) to inhibit further
956 proteolysis. Whole cell lysates were electrophoresed on a SDS-12%-PAGE gel and
957 subjected to Western immunoblotting with anti-IcsA antibody.

958

959

(a)



(b)





Figure 1

(a)

| | MYRM724 | | MYRM729 | | MYRM725 | | MYRM730 | | MYRM726 | | MYRM731 | | MYRM727 | | MYRM732 | | MYRM728 | | MYRM733 | |
|----------|--------------------------|---|---------|---|----------------------------|---|---------|---|----------------------------|---|---------|---|----------------------------|---|---------|---|----------------------------|---|---------|---|
| | <i>IcsA_{WT}</i> | | | | <i>IcsA_{i633}</i> | | | | <i>IcsA_{i643}</i> | | | | <i>IcsA_{i677}</i> | | | | <i>IcsA_{i716}</i> | | | |
| pACYC184 | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - |
| pRMA727 | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + | - | + |



(b)




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

Supplementary Material

Absence of O-antigen suppresses *Shigella flexneri* lcsA autochaperone region mutations

Min Yan Teh, Elizabeth Ngoc Hoa Tran, and Renato Morona*

***Corresponding Author**

Discipline of Microbiology and Immunology, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia 5005.

Phone: + 61 (8) 8313 4151

Fax: + 61 (8) 8313 7532

E-mail: renato.morona@adelaide.edu.au.

Table S1. Oligonucleotides used in this study

| Primer | Oligonucleotide sequence (5' – 3')[#] | Target | Nucleotide positions |
|---------------|---|---------------------------|-----------------------------|
| lacZ_TGA_F | tctccaacccctctcatgcat g aggggctagaga | icsA-TGA- <i>lacZ</i> | - ‡ |
| lacZ_TGA_R | tctctagcccc t catgcatgagaggggtggaaga | icsA-TGA- <i>lacZ</i> | - ‡ |
| ET9 | ggccatggacattcaacccaaaaag | <i>icsP</i> | 220267 [§] |
| ET10 | gcggatccaaaaatatactttatacctgcg | <i>icsP</i> | 221244 [§] |
| ET22 | gcggtaccataaagtaagaagatcatggac | 16bp upstream <i>icsP</i> | 220251 [§] |
| ET25 | gggaagctttcaaaaaatatactttatacctg | <i>icsP</i> | 221247 [§] |

[#] Underlined and bolded sequences indicate the nucleotides that undergo site-directed mutagenesis

[‡] Contact authors for the DNA sequence

[§] Nucleotide positions based on the sequence of the *S. flexneri* 2a strain 301 virulence plasmid pCP301 – GeneBank accession # AF386526